Text Search: Search by:

Refine your search with filters

Year:

Category:

All

Congress Abstracts

Tools & Skills

Publications

Congress Presentations

Videos & Podcasts

Quicksearch

DOP025: Clinical response to anti-MMP9 antibody (GS-5745) is accompanied by histologic improvement in ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

W. Sandborn^{1, 2}, B. Bhandari³, R. Fogel⁴, J. Onken⁵, E. Yen⁶, E. Huntzicker⁶, Y. Xin⁶, D. French⁶, J. Silverman⁶, B. Kanwar⁶, M. Subramanian⁶, J. McHutchison⁶, S. Lee⁷, L. Shackelton⁸, L. Stitt⁸, R. Pai⁹, B. Levesque*², G. D’Haens^{10, 11}, B. Feagan^{8, 12}

¹University of California, San Diego, California, United States, ²Robarts Clinical Trials, San Diego, California, United States, ³Delta Research Partners, Monroe, Louisiana, United States, ⁴Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, United States, ⁵Duke University Medical Centre, Durham, North Carolina, United States, ⁶Gilead Sciences, Inc, Foster City, California, United States, ⁷University of Washington, Seattle, Washington, United States, ⁸Robarts Clinical Trials, London, Ontario, Canada, ⁹Mayo Clinic Arizona, Scottsdale, Arizona, United States, ¹⁰Academic Medical Centre, Amsterdam, Canada, ¹¹Robarts Clinical Trials, Amsterdam, Netherlands, ¹²University of Western Ontario, London, Ontario, Canada

DOP026: The Toll-like-receptor 9 agonist DIMS0150 demonstrates therapeutic efficacy for the patient-reported outcome measures PRO-2 and ClinPRO in moderate-to-severe active ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

R. Atreya*¹, S. Bloom², F. Scaldaferi³, V. Gerardi⁴, C. Admyre⁵, A. Karlsson⁵, T. Knittel⁵, J. Kowalski⁵, M. Lukas⁶, R. Löfberg⁷, R. Petryka⁸, R. Schnabel⁹, U. Seidler¹⁰, S. Nancey¹¹, M. Neurath¹, C. Hawkey¹²

¹University of Erlangen-Nuernberg, Department of Medicine 1, Erlangen, Germany, ²University College London Hospital, Department of Gastroenterology, London, United Kingdom, ³Catholic University of Rome, Internal Medicine Department / Gastroenterology Division, Rome, Italy, ⁴Catholic University of Rome, Rome, Italy, ⁵Index Pharmaceuticals, Stockholm, Sweden, ⁶IBD Clinical and Research Centre, Clinical Centre Isacre Lighthouse, Prague, Czech Republic, ⁷Karolinska Institute and Sophiahemmet, Stockholm, Sweden, ⁸8NZOZ Vivamed, Warsaw, Poland, ⁹Pannonia Maganorvosi Centrum, Budapest, Hungary, ¹⁰MHH, Department of Gastroenterology, Hepatology, and Endocrinology, Hannover, Germany, ¹¹Lyon-Sud Hospital, Department of Gastroenterology, Lyon, France, ¹²Nottingham University Hospitals, Department of Gastroenterology, Nottingham, United Kingdom

DOP027: Large-scale drug screen reveals benzimidazole anti-helminthics as potential anti-TNF co-therapyECCO '16 Amsterdam

Year: 2016

Authors:

M. Wildenberg*¹, A. Levin², A. Ceroni³, Z. Guo², F. Bloemendaal², D. Ebner³, G. van den Brink¹

¹Academic Medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands, ²Academic Medical Centre, Tytgat Institute, Amsterdam, Netherlands, ³Oxford University, Target Discovery Institute, Oxford, United Kingdom

DOP028: Efficacy and safety of biosimilar infliximab after one year: results from a prospective nationwide cohortECCO '16 Amsterdam

Year: 2016

Authors:

K. Gecse*¹, Z. Vegh¹, Z. Kurti¹, M. Rutka², K. Farkas², J. Banai³, L. Bene⁴, B. Gasztonyi⁵, P. A. Golovics¹, T. Kristof⁶, L. Lakatos⁷, P. Miheller⁸, F. Nagy⁹, K. Palatka¹⁰, M. Papp¹¹, L. Lakner¹², A. Patai¹³, A. Salamon¹⁴, T. Szamosi³, Z. Szepes⁹, B. Szalay¹⁵, G. T. Toth¹⁶, A. Vincze¹⁷, T. Molnar², P. Lakatos¹

¹Semmelweis University, First Department of Medicine, Budapest, Hungary, ²University of Szeged, First Department of Medicine, Szeged, Hungary, ³Military Hospital, State Health Centre, Department of Gastroenterology, Budapest, Hungary, ⁴Peterfy Hospital, First Department of Medicine, Budapest, Hungary, ⁵Zala County Hospital, Second Department of Medicine, Zalaegerszeg, Hungary, ⁶B-A-Z County and University Teaching Hospital, Second Department of Medicine, Miskolc, Hungary, ⁷Csolnoky F. Province Hospital, Department of Medicine, Veszprem, Hungary, ⁸Semmelweis University, Second Department of Medicine, Budapest, Hungary, ⁹University of Szeged, First Department of Internal Medicine, Szeged, Hungary, ¹⁰University of Debrecen, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary, ¹¹University of Debrecen, Institute of Internal Medicine, Department of Gastroenterology, Debrecen, Hungary, ¹²Markusovszky Hospital, Department of Medicine and Gastroenterology, Szombathely, Hungary, ¹³Markusovszky Hospital, First Department of Medicine and Gastroenterology, Szombathely, Iceland, ¹⁴Tolna County Teaching Hospital, First Department of Gastroenterology, Szekszard, Hungary, ¹⁵Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary, ¹⁶Janos Hospital, Department of Gastroenterology, Budapest, Hungary, ¹⁷University of Pécs, First Department of Medicine, Pécs, Hungary

DOP029: Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximabECCO '16 Amsterdam

Year: 2016

Authors:

M. Bettey¹, L. Downey¹, C. Underhill¹, J. Callaghan¹, M. Rush², I. Ahmed¹, F. Cummings*¹

¹University Hospital Southampton NHS Trust, Department of Gastroenterology, Southampton, United Kingdom, ²University of Southampton, Department of Gastroenterology, Southampton, United Kingdom

DOP030: Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort studyECCO '16 Amsterdam

Year: 2016

Authors:

L. Smits*, L. Derikx, J. Drenth, D. de Jong, A. van Esch, F. Hoentjen

Radboud University Medical Centre, Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Nijmegen, Netherlands

DOP031: Efficacy of infliximab biosimilar CT-P13 therapy on mucosal healing in ulcerative colitis: data from 2 Central European countriesECCO '16 Amsterdam

Year: 2016

Authors:

K. Farkas¹, M. Rutka¹, P.A. Golovics², Z. Végh², B.D. Lovász², T. Nyári³, K.B. Gecse², M. Kolar^{4, 5}, M. Bortlik^{4, 6}, D. Duricova^{4, 7}, N. Machkova⁴, V. Hruba⁴, M. Lukas⁴, K. Mitrova^{4, 8}, K. Malickova⁹, A. Bálint¹, F. Nagy¹, R. Bor*¹, A. Milassin¹, Z. Szepes¹, K. Palatka¹⁰, P.L. Lakatos², M. Lukas^{4, 9}, T. Molnár¹

¹University of Szeged, First Department of Medicine, Szeged, Hungary, ²Semmelweis University, First Department of Medicine, Budapest, Hungary, ³University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary, ⁴IBD Clinical and Research Centre, Iscare a.s, Prague, Czech Republic, ⁵Charles University, First Medical Faculty, Prague, Czech Republic, ⁶Military Hospital, Charles University, Department of Internal Medicine, Prague, Czech Republic, ⁷ First Medical Faculty, Charles University, Institute of Pharmacology, Prague, Czech Republic, ⁸Faculty Hospital Motol, 2nd Medical Faculty, Charles University, Department of Paediatrics, Prague, Czech Republic, ⁹ First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic, ¹⁰University of Debrecen, Second Department of Medicine, Debrecen, Hungary

DOP032: Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safeECCO '16 Amsterdam

Year: 2016

Authors:

M. Kolar*¹, D. Duricová², M. Brotlik¹, V. Hruba¹, N. Machkova¹, K. Mitrova¹, K. Malickova³, M. Lukas¹, M. Lukas¹

¹Charles University, IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic, ²Charles University, IBD Clinical and Research Centre, Iscare, Prague, Czech Republic, ³ First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic

DOP033: Immunogenicity profile and predictors of TLs and ADA development of biosimilar infliximab during the first 6 months of the therapy: results from a prospective nationwide cohortECCO '16 Amsterdam

Year: 2016

Authors:

B. Lovasz*¹, Z. Kurti¹, M. Rutka², Z. Vegh¹, K. Gecse¹, K. Farkas², J. Banai³, L. Bene⁴, B. Gasztonyi⁵, T. Kristof⁶, L. Lakatos⁷, P. Miheller⁸, K. Palatka⁹, A. Patai¹⁰, A. Salamon¹¹, T. Szamosi³, Z. Szepes¹², E. Biro¹³, G.T. Toth¹⁴, A. Vincze¹⁵, T. Molnar², P. Lakatos¹

¹Semmelweis University, First Department of Medicine, Budapest, Hungary, ²University of Szeged, First Department of Medicine, Szeged, Hungary, ³Military Hospital, State Health Centre, Department of Gastroenterology, Budapest, Hungary, ⁴Peterfy Hospital, First Department of Medicine, Budapest, Hungary, ⁵Zala County Hospital, Second Department of Medicine, Zalaegerszeg, Hungary, ⁶B-A-Z County and University Teaching Hospital, Second Department of Medicine, Miskolc, Hungary, ⁷Csolnoky F. Province Hospital, Department of Medicine, Veszprem, Hungary, ⁸Semmelweis University, Second Department of Medicine, Budapest, Hungary, ⁹University of Debrecen, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary, ¹⁰Markusovszky Hospital, First Department of Medicine and Gastroenterology, Szombathely, Iceland, ¹¹Tolna County Teaching Hospital, First Department of Gastroenterology, Szekszard, Hungary, ¹²University of Szeged, First Department of Internal Medicine, Szeged, Hungary, ¹³Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary, ¹⁴Janos Hospital, Department of Gastroenterology, Budapest, Hungary, ¹⁵University of Pécs, First Department of Medicine, Pécs, Hungary

DOP034: Comparative effectiveness of infliximab and adalimumab in Crohn’s disease: results from a real-life population-based cohortECCO '16 Amsterdam

Year: 2016

Authors:

S. Jeuring*^{1, 2}, D. Wintjens¹, T. Van den Heuvel^{1, 2}, M. Zeegers^{3, 4},  W. Hameeteman¹, M. Romberg-Camps⁵, L. Oostenbrug⁶, A. Masclee^{1, 2}, D. Jonkers^{1, 2}, M. Pierik^{1, 2}

¹Maastricht University Medical Centre, Internal Medicine - Division of Gastroenterology and Hepatology, Maastricht, Netherlands, ²Maastricht University Medical Centre, NUTRIM - School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, ³Maastricht University Medical Centre, Complex Genetics - School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht, Netherlands, ⁴Maastricht University Medical Centre, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands, ⁵Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Sittard-Geleen, Netherlands, ⁶Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Heerlen, Netherlands

DOP035: Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα –blocking agentsECCO '16 Amsterdam

Year: 2016

Authors:

P. Molander*^{1, 2}, M. Färkkilä^{2, 3}, H. Kemppainen⁴, T. Blomster⁵, A. Jussila⁶, H. Mustonen⁷, T. Sipponen^{2, 3}

¹Helsinki University Central Hospital, Peijas Hospital, Gastroenterology, Vantaa, Finland, ²University of Helsinki, Helsinki, Finland, ³Helsinki University Central Hospital, Abdominal Centre, Clinic of Gastroenterology, Helsinki, Finland, ⁴Turku University Central Hospital, Department of Gastroenterology, Turku, Finland, ⁵Oulu University Hospital, Department of Gastroenterology, Oulu, Finland, ⁶Tampere University Hospital, Department of Gastroenterology and Alimentary Tract Surgery, Tampere, Finland, ⁷Helsinki University Central Hospital, Department of Surgery, Helsinki, Finland

DOP036: Infliximab discontinuation is associated with a higher risk for relapse in patients with ulcerative colitis in remission: a multinational collaborative retrospective studyECCO '16 Amsterdam

Year: 2016

Authors:

G. Fiorino*¹, P. Ellul², M. Muscat², P. Karatzas³, M. Silva⁴, A. Peixoto⁴, C. Felice⁵, F. Bossa⁶, P.L. Lakatos⁷, S. Sebastian⁸, B. Ungar⁹, F. Furfaro¹, K. Karmiris¹⁰, K.H. Katsanos¹¹, P. Navarro Cortes¹², M.M. Boscà Watts¹², D.K. Christodoulou¹¹, G. Maconi¹³, U. Kopylov⁹, A. Armuzzi⁵, F. Magro⁴, G. Mantzaris³, S. Ben-Horin⁹, S. Danese^{1, 14}

¹Humanitas Research Hospital, IBD Centre, Gastroenterology, Rozzano, Milan, Italy, ²Mater Dei Hospital, Department of Gastroenterology, Msida, Malta, ³Evangelismos Hospital, Department of Gastroenterology, Athens, Greece, ⁴Centro Hospitalar São João, Oporto, Portugal, Gastrenterology, Oporto, Portugal, ⁵Complesso Integrato Columbus, Gemelli Hospital Catholic University Foundation, IBD Unit, Rome, Italy, ⁶Casa Sollievo della Sofferenza Hospital, Division of Gastroenterology, San Giovanni Rotondo, Italy, ⁷Semmelweis University, 1st Department of Medicine, Budapest, Hungary, ⁸Hull & East Yorkshire NHS Trust, Hull & York Medical School, Hull, United Kingdom, ⁹Sheba Medical Centre, Gastroenterology, Tel Hashomer, Tel-Aviv, Israel, ¹⁰Venizelion General Hospital, Department of Gastroenterology, Heraklion, Greece, ¹¹University Hospital of Ioannina - Greece, Department of Gastroenterology, Ioannina, Greece, ¹²University Clinic Hospital of Valencia, Department of Gastroenterology, Valencia, Spain, ¹³Luigi Sacco University Hospital, Department of Gastroenterology, Milan, Italy, ¹⁴Humanitas University, Department of Biomedical Sciences, Rozzano, Italy

DOP037: Excess steroid use in IBD: too much, how much, and why? Results from a UK nationwide auditECCO '16 Amsterdam

Year: 2016

Authors:

T. Raine¹, A. Bassi², E. Fogden³, B. Hayee⁴, J. K. Limdi⁵, H. Ludlow⁶, S. McLaughlin⁷, G. C. Parkes⁸, P. Patel⁹, M. Smith¹⁰, C. Selinger*¹¹

¹Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology Research, Cambridge, United Kingdom, ²Whiston Hospital, Department of Gastroenterology, Prescot, United Kingdom, ³Sandwell District General Hospital, Department of Gastroenterology, West Bromwich, United Kingdom, ⁴King’s College Hospital, Department of Gastroenterology, London, United Kingdom, ⁵Pennine Acute Hospitals NHS Trust, Department of Gastroenterology, Manchester, United Kingdom, ⁶University Hospital Llandough, Department of Gastroenterology, Penarth, Cardiff, United Kingdom, ⁷Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom, ⁸Barts and The London, Queen Mary’s School of Medicine and Dentistry, Department of Gastroenterology, London, United Kingdom, ⁹Epsom General Hospital, Department of Gastroenterology, Epsom, United Kingdom, ¹⁰Brighton and Sussex University Hospitals Trust, Digestive Diseases, Hove, East Sussex, United Kingdom, ¹¹St James University Hospital, Gastroenterology, Leeds, United Kingdom

DOP038: Analytical and clinical validation of a rapid point-of-care assay for infliximab quantification in patients with ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

T. Van Stappen*¹, L. Bollen¹, N. Vande Casteele¹, K. Papamichail^{1, 2},  N. Geukens¹, C. Barthel³, Y. Kölmel³, N. Zali³, S. Rameil³, G. Van Assche², M. Ferrante², S. Vermeire², A. Gils¹

¹KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ²UZ Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium, ³R-Biopharm AG, Darmstadt, Germany

DOP039: Point-of-care monitoring of infliximab trough levels in capillary fingerstick blood of patients with inflammatory bowel disease (IBD)ECCO '16 Amsterdam

Year: 2016

Authors:

J. Maljaars*¹, C. de Dood², S. van der Burg¹, A. van der Meulen¹, H. Tanke², P. Corstjens²

¹LUMC, Gastroenterology-Hepatology, Leiden, Netherlands, ²Leiden University Medical Centre, Department of Molecular Cell Biology Geb. 1, Leiden, Netherlands

DOP040: Effects of education and information on vaccination behaviour in IBD patientsECCO '16 Amsterdam

Year: 2016

Authors:

S. Coenen*¹, E. Weyts¹, C. Jorissen², P. De Munter³, M. Noman¹, V. Ballet¹, S. Vermeire¹, G. Van Assche¹, M. Ferrante¹

¹UZ Leuven, Gastroenterology, Leuven, Belgium, ²KU Leuven, Leuven, Belgium, ³UZ Leuven, Leuven, Belgium

DOP041: Impact of an education programme on IBD patient’s skills: one year results of the ECIPE randomised, controlled multicentre study.ECCO '16 Amsterdam

Year: 2016

Authors:

J. Moreau¹, L. Marthey², C. Trang³, M. Nachury⁴, R. Altwegg⁵, J.-C. Grimaud⁶, S. Orempuller¹, J. Filippi⁷, A. Aubourg⁸, C. Baudry⁹, P. Seksik¹⁰, X. Roblin¹¹, S. Nahon¹², G. Savoye¹³, B. Mesnard¹⁴, C. Stefanescu¹⁵, M. Simon¹⁶, B. Coffin¹⁷, J.-L. Dupas¹⁸, S. Chevret¹⁹, M. Allez*²⁰

¹Rangueil Hospital, Department of Gastroenterology, Toulouse, France, ²Bicetre Hospital, Department of Gastroenterology, Le Kremlin Bicêtre, France, ³CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, ⁴Huriez Hospital, Department of Gastroenterology, Lille, France, ⁵Saint Eloi Hospital, Department of Hepatology and Gastroenterology, Montpellier, France, ⁶Nord Hospital, Department of Gastroenterology, Marseille, France, ⁷Archet Hospital, Department of Gastroenterology and Nutrition, Nice, France, ⁸Trousseau University Hospital, Department of Gastroenterology, Tours, France, ⁹Saint-Louis Hospital, Department of Gastroenterology and Hepatology, Paris, France, ¹⁰St. Antoine Hospital, Department of Gastroenterology, Paris, France, ¹¹CHU St Etienne, Department of Gastroenterology, Saint-Etienne, France, ¹²Montfermeil Hospital, Department of Gastroenterology, Montfermeil, France, ¹³Charles Nicolle Hospital, Department of Gastroenterology, Rouen, France, ¹⁴CH Dron, Department of Gastroenterology, Tourcoing, France, ¹⁵Beaujon Hospital, Department of Gastroenterology, Paris, France, ¹⁶Montsouris Mutualist Institute, Department of Gastroenterology, Paris, France, ¹⁷Louis Mourier Hospital APHP, Department of Gastroenterology and Hepatology, Colombes, France, ¹⁸Nord Hospital, Department of Gastroenterology, Amiens, France, ¹⁹Saint-Louis Hospital, Department of Biostatistics, Paris, France, ²⁰Saint-Louis Hospital, Department of Gastroenterology, Paris, France

DOP042: Most anti-TNF injectors are stored under suboptimal conditions at homeECCO '16 Amsterdam

Year: 2016

Authors:

M. de Jong^{*1, 2}, M. Pierik^{1, 2}, A. Peters³, M. Roemers⁴, F. van der Heijden⁵, V. Hilhorst⁶, A. van Tubergen^{7, 8}

¹Maastricht University Medical Centre+, Department of Internal Medicine, division of Gastroenterology and Hepatology, Maastricht, Netherlands, ²Maastricht University Medical Centre+, NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, ³Maastricht University Medical Centre+, Department of Internal Medicine, Maastricht, Netherlands, ⁴AntTail, Utrecht, Netherlands, ⁵MSD, Haarlem, Netherlands, ⁶Maastricht University Medical Centre+, Department of Clinical Pharmacy & Toxicology, Maastricht, Netherlands, ⁷Maastricht University Medical Centre+, Department of Internal Medicine, division of Rheumatology, Maastricht, Netherlands, ⁸Maastricht University Medical Centre+, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands

DOP043: Nonadherence to anti-TNF therapy predicts clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre studyECCO '16 Amsterdam

Year: 2016

Authors:

M. van der Have*¹, B. Oldenburg¹, A. A. Kaptein², J. M. Jansen³, R. C. Scheffer⁴, S. A. van Tuyl⁵, A. E. van der Meulen - de Jong⁶, M. Pierik⁷, P. D. Siersema¹, M. G. van Oijen^{1, 8}, H. H. Fidder¹

¹University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ²Leiden University Medical Centre, Section Medical Psychology, Leiden, Netherlands, ³Onze Lieve Vrouwe Gasthuis, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, ⁴Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, ‘s Hertogenbosch , Netherlands, ⁵Diakonessenhuis, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ⁶Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, ⁷Maastricht University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, Netherlands, ⁸Academic Medical Centre, Department of Medical Oncology, Amsterdam, Netherlands

DOP044: Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

K. Carlsen*^{1, 2}, C. Jakobsen², L. F. Hansen², A. Paerregaard², L. B. Riis³, P. S. Munkholm⁴, V. Wewer²

¹Hvidovre Hospital, Paediatric, Hvidovre, Denmark, ²Hvidovre Hospital, Department of Paediatrics, Hvidovre, Denmark, ³Herlev Hospital, Department of Pathology, Herlev, Denmark, ⁴North Zealand Hospital, Department of Gastroenterology, Frederikssund, Denmark